Skip to main content

Advertisement

SpringerLink
Log in

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

  • Ongoing Clinical Studies
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. HELIOS – Klinikum Erfurt, 2. Medizinische Klinik, Department of Hematology/Oncology, Nordhäuserstrasse 74, 99089 Erfurt, Germany, Germany

    M. Herold, G. Dölken, F. Fiedler, A. Franke, M. Freund, W. Helbig & R. Pasold

Authors
  1. M. Herold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Dölken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Helbig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Pasold
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herold, M., Dölken, G., Fiedler, F. et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 82, 77–79 (2003). https://doi.org/10.1007/s00277-002-0581-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-002-0581-1

Keywords

Search

Navigation